Skip to content
Neuroscience — News — health-and-wellness — Science — Engineering — technology — Mental — Journal — Research

Compact Genetic Modification: Streamlined RNA Alteration Techniques

Neuroscientists at MIT's McGovern Institute innovate CRISPR technology with a condensed Cas7-11 enzyme, enabling the accommodating of the enzyme within a solitary viral vector for potential therapeutic uses.

,   and  Administrator
3 min read
Neuroscientists at MIT's McGovern Institute have expanded the CRISPR toolkit by developing a...
Neuroscientists at MIT's McGovern Institute have expanded the CRISPR toolkit by developing a miniature Cas7-11 enzyme. This tiny enzyme can be effectively enclosed within a solitary viral vector for potential therapeutic purposes.

Compact Genetic Modification: Streamlined RNA Alteration Techniques

Revamped Recap:

Last year, a team of brain researchers from MIT's McGovern Institute and the University of Tokyo made a game-changing discovery: the compact version of Cas7-11, a CRISPR enzyme that can edit RNA with surgical precision, all while leaving cells unharmed. This recent breakthrough offers a promising avenue for therapeutic RNA manipulation.

According to Omar Abudayyeh, the lead researcher of the project and a McGovern Fellow, this new Cas7-11 variant is small enough to fit inside a single viral vector, making it a practical option for editing RNA within living cells.

The researchers revealed their findings in a journal called Cell on May 27, 20XX. They also provided a detailed analysis of the original Cas7-11 structure to help further understand the enzymes and explore new ways to modify their function down the line.

Why is this important? RNA editing could offer a more effective approach for certain research and clinical purposes compared to traditional DNA editing. While DNA edits are usually permanent, RNA is a more transient molecule that offers temporary gene modifications, offering benefits for a wide range of temporary diseases or disorders.

Before Abudayyeh and his team's discovery, the only available enzyme for RNA editing (Cas13) had one major drawback: it tended to cut up all the RNA around its target gene, leading to undesirable side effects.

The discovery of Cas7-11 paves the way for a more precise form of RNA editing, akin to the Cas9 enzyme for DNA editing. However, the massive size of the original Cas7-11 protein prevented it from fitting inside a single viral vector, limiting its therapeutic applications.

Through the use of cryo-electron microscopy, Abudayyeh, Gootenberg, and Nishimasu from the University of Tokyo, determined the overall structure of Cas7-11 and identified a section of the protein that wasn't serving any functional role. This discovery provided the basis for re-engineering Cas7-11 to create a compact version (Cas7-11S), which has been shown to effectively target RNA in mammalian cells.

The researchers are now focusing on future studies involving proteins that interact with Cas7-11 and plan to continue working towards the use of Cas7-11 for therapeutic applications.

As Abudayyeh put it, "Imagine you could have an RNA gene therapy, and when you take it, it modifies your RNA, but when you stop taking it, that modification stops. This is really just the beginning of enabling that tool set."

This research was funded by several organizations, including the McGovern Institute Neurotechnology Program, K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience, G. Harold and Leila Y. Mathers Charitable Foundation, MIT John W. Jarve (1978) Seed Fund for Science Innovation, FastGrants, Basis for Supporting Innovative Drug Discovery and Life Science Research Program, JSPS KAKENHI, Takeda Medical Research Foundation, and Inamori Research Institute for Science.

Additional Insights:

CRISPR systems, including Cas proteins, are well-known for their role in RNA-guided gene editing and immune functions in bacteria. These systems employ CRISPR RNA (crRNA) for sequence specificity and programmability[1]. CRISPR systems, such as Cas7-11, have revolutionized gene editing and RNA manipulation in various organisms by offering precise tools for modifying genes and genomes[5]. Modifications or enhancements to CRISPR systems, like compact versions, could potentially improve the efficiency, specificity, or applicability of RNA editing technology in living cells.

  1. The breakthrough discovery of the compact version of Cas7-11, a CRISPR enzyme, offers a promising avenue for therapeutic RNA manipulation in health-and-wellness, with potential benefits for a wide range of temporary diseases or disorders.
  2. The small size of Cas7-11 opens up practical options for editing RNA within living cells, providing a more effective approach for certain research and clinical purposes compared to traditional DNA editing.
  3. In the journal Cell, the researchers revealed that the new Cas7-11 variant is a significant step forward for the field of neuroscience and innovation, as RNA editing could potentially lead to new therapies and treatments.
  4. The reduction in size of Cas7-11 makes it a more viable option for editing RNA, overcoming the major drawback of the previously available Cas13 enzyme, which tended to cut up all the RNA around its target gene.
  5. The researchers provide a detailed analysis of the original Cas7-11 structure in their article, with the goal of further understanding the enzymes and exploring new ways to modify their function.
  6. Future studies involving proteins that interact with Cas7-11 will focus on exploring its therapeutic applications, with the aim of eventually using it for mental health treatments and other health and wellness purposes.
  7. The discovery of Cas7-11 and its implications for the field of science and technology have been funded by several key organizations, including the McGovern Institute Neurotechnology Program, which has played a significant role in this groundbreaking research.

Read also:

    Related

    Latest